Tag: Crohn’s Disease
FDA Approves Tremfya for Active Crohn Disease in Adults
Tremfya is the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for Crohn disease
Inflammatory Bowel Disease Tied to Higher Risk for Heart Disease
Nearly doubled risk for new ischemic heart disease seen in men with inflammatory bowel disease
FDA Approves Omvoh for Moderately to Severely Active Crohn Disease
Approval based on results from phase 3 VIVID-1 trial, in which end points of clinical remission and endoscopic response were met at one year
Early Anti-TNFα Therapy Cuts Perianal Fistula Complications in Pediatric Crohn Disease
Odds of complications significantly reduced with early anti-TNFα therapy, especially in those with perianal lesions
Study Compares Surgical Techniques for Crohn Disease
Longest length of stay, increased odds of wound complications seen for small bowel resection versus strictureplasty and combined approach
Risankizumab Noninferior, Superior to Ustekinumab for Crohn Disease
Risankizumab noninferior for clinical remission at week 24, superior for endoscopic remission at week 48
Top-Down Treatment Superior for Crohn Disease
One-year outcomes better with early combined infliximab + immunomodulator vs. accelerated step-up treatment
Higher Use of Any Rx Medications Seen Years Before IBD Diagnosis
Findings strongest for Crohn disease with ties to multisystem organ involvement
Persistent Fluorinated Chemicals Tied to Higher Risk for Inflammatory Bowel Disease
Odds for Crohn disease and ulcerative colitis increased with higher serum perfluoroalkyl and polyfluoroalkyl substance levels up to 10 years before diagnosis
Histologic Inflammation With IBD Tied to Serious Infections
Authors say achieving histologic remission for both Crohn disease and ulcerative colitis may reduce the risk for serious infections
